Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00673790 · ClinicalTrials.gov registry record · Phase 4
The Blood Pressure and Metabolic Effects of Nebivolol in Hypertensive Patients With Impaired Glucose Tolerance or Impaired Fasting Glucose
A Phase 4 study, sponsored by Forest Laboratories.
- Completed
- Registry status
- Phase 4
- Development phase
- 537
- Enrollment target
NCT00673790 is a Phase 4 study that has completed, run by Forest Laboratories. The registered enrollment target is 537 participants.
The verdict
NCT00673790, a Phase 4 study, has completed, sponsored by Forest Laboratories.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 537 participants
- Enrollment target
Study Summary
This study is being done to see if the blood pressure and metabolic effects of an approved drug nebivolol is comparable to that of another approved drug hydrochlorothiazide (HCTZ) and placebo in hypertensive patients.
Interventions
- DRUG Nebivolol with concomitant losartan or lisinopril
- DRUG HCTZ with concomitant losartan or lisinopril
- DRUG Placebo with concomitant losartan or lisinopril
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 537 participants |
| Start Date | 2008-05-15 |
| Est. Completion | 2010-07-09 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00673790
The ClinicalTrials.gov registry entry for NCT00673790 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 537 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Forest Laboratories, which has 145 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Nebivolol with concomitant losartan or lisinopril is the first listed.
NCT00673790 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00673790 about?
NCT00673790 is a clinical study titled "The Blood Pressure and Metabolic Effects of Nebivolol in Hypertensive Patients With Impaired Glucose Tolerance or Impaired Fasting Glucose". This study is being done to see if the blood pressure and metabolic effects of an approved drug nebivolol is comparable to that of another approved drug hydrochlorothiazide (HCTZ) and placebo in hypertensive patients.
What is the current status of trial NCT00673790?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 537 participants. The study started on 2008-05-15. Estimated completion is 2010-07-09.
What interventions are being tested in trial NCT00673790?
The interventions under investigation include: Nebivolol with concomitant losartan or lisinopril (DRUG), HCTZ with concomitant losartan or lisinopril (DRUG), Placebo with concomitant losartan or lisinopril (DRUG).
Who is sponsoring clinical trial NCT00673790?
This trial is sponsored by Forest Laboratories, which has 145 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.